DETERMINATION OF PROTEIN AGGREGATION FROM THE CONCENTRATION DEPENDENCE OF DELTA G
The present invention relates to, among other things, methods and systems for recognizing and characterizing protein aggregation processes at the earliest possible time and use of such new methods and systems for (1) the identification and selection of protein formulations that minimize aggregation and extend long-term stability and (2) the identification of protein variants with the lowest tendency to aggregate.
1 - 17 . (canceled)
18 . A method for preparing a pharmaceutically acceptable protein formulation that minimizes protein aggregation, comprising:
providing a plurality of first solutions comprising increasing concentrations of a protein; measuring an observable property for each solution in said plurality of first solutions; determining ΔG for the conformational stability of said protein at each concentration in said plurality of first solutions based on said observable property; creating a correlation between ΔG and each concentration of said protein in said plurality of first solutions; and using said correlation to determine the amount or fraction of said protein that is aggregated in said plurality of first solutions;
providing a plurality of at least second solutions comprising increasing concentrations of said protein; measuring an observable property for each solution in said plurality of at least second solutions; determining ΔG for the conformational stability of said protein at each concentration in said plurality of at least second solutions based on said observable property; creating a correlation between ΔG and each concentration of said protein for in said plurality of second solutions; and using said correlation to determine the amount or fraction of said protein that is aggregated,
wherein said plurality of at least second solutions differs from said plurality of first solutions in one or more conditions selected from the group consisting of buffer composition, buffer strength, pH, ionic strength, excipient composition, excipient concentration, chemical denaturant composition, and chemical denaturant concentration;
using the correlations between ΔG and each concentration of said protein to determine a concentration of said protein that maximizes ΔG and minimizes ΔG's protein-concentration dependence; and
preparing a pharmaceutically acceptable protein formulation that comprises said concentration of said protein that maximizes ΔG and minimizes ΔG's protein-concentration dependence and which minimizes protein aggregation.
19 . The method of claim 18 , further comprising a step of selecting one or more conditions that further maximizes ΔG and minimizes ΔG's protein-concentration dependence selected from the group consisting of buffer composition, buffer strength, pH, ionic strength, excipient composition, and excipient concentration.
20 . The method of claim 18 , wherein said plurality of at least second solutions differs from said plurality of first solutions in at least chemical denaturant concentration.
21 . A pharmaceutically acceptable protein formulation having said one or more conditions and said concentration of said protein as determined by the method of claim 19 .
22 . A method for determining a stable protein variant in a plurality of variants of said protein comprising steps of:
providing a plurality of first solutions comprising increasing concentrations of a first protein variant; inducing physical or chemical denaturation; measuring an observable property for each solution in said plurality of first solutions; determining ΔG for the conformational stability of said first protein variant at each concentration in said plurality of first solutions based on said observable property; creating a correlation between ΔG and each concentration of said first protein variant; and using said correlation to determine the amount or fraction of said protein that is aggregated; and
providing a plurality of at least second solutions comprising increasing concentrations of at least a second protein variant; inducing physical or chemical denaturation; measuring an observable property for each solution in said plurality of at least second solutions; determining ΔG for the conformational stability of said at least second protein variant at each concentration in said plurality of at least second solutions based on said observable property; creating a correlation between ΔG and each concentration of said at least second protein variant; and using said correlation to determine the amount or fraction of said protein that is aggregated
wherein each solution in said plurality of first solutions differs in one or more conditions selected from the group consisting of buffer composition, buffer strength, pH, ionic strength, excipient composition, excipient concentration, chemical denaturant composition, and chemical denaturant concentration and each solution in said plurality of at least second solutions differs in said one or more conditions;
wherein the protein variant having a lesser amount or fraction of aggregated protein is determined to be the stable protein variant.
23 . The method of claim 22 , wherein said protein variants are monoclonal antibodies obtained from different hybridoma clones.
24 . The method of claim 22 , wherein said protein variants comprise proteins that differ in one or more glycosylated amino acids or comprise proteins that differ by attachment of one or more small molecules.
25 . The method of claim 22 , wherein each solution in said plurality of first solutions differs in at least chemical denaturant concentration and each solution in said plurality of at least second solutions differs in at least chemical denaturant concentration.